Skip to main content
SpringerLink
Log in

Autologous and Allogeneic Hematopoieitic Cell Transplantation: Risk of Second Malignancies

  • Chapter
  • First Online:
Stem Cells and Cancer Stem Cells, Volume 11

Part of the book series: Stem Cells and Cancer Stem Cells ((STEM,volume 11))

  • 1248 Accesses

Abstract

With improved measures for supportive care and an increasing number of hematopoietic cell transplants being performed for both malignant and non-malignant disorders, many patients are surviving for longer periods of time following transplantation. Unfortunately, second malignancies in survivors are well-described complications that often carry a very poor prognosis and thus are devastating for patients and their families. The magnitude of risk ranges from 4- to 11-fold that of the general population. The types of second malignancies, current understanding of their pathogenesis, prognosis and available therapies are detailed here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL (2003) New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 21:1352–1358

    Article  PubMed  Google Scholar 

  • Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fos M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J (2008) Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 111:94–100

    Article  PubMed  CAS  Google Scholar 

  • Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung H, Kashyap A, Krishnan A, Molina A, Nademanee A, Niland JC, Parker PA, Snyder DS, Spielberger R, Stein A, Forman SJ (2001) Solid cancers after bone marrow transplantation. J Clin Oncol 19:464–471

    PubMed  CAS  Google Scholar 

  • Bianchi E, Pascual M, Nicod M, Delaloye AB, Duchosal MA (2008) Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation 85:707–712

    Article  PubMed  Google Scholar 

  • Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF (2010) Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 24:2056–2062

    Article  PubMed  CAS  Google Scholar 

  • Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R (2009) Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 27:791–798

    Article  PubMed  Google Scholar 

  • Cohen JI (2000) Epstein-Barr virus infection. N Eng J Med 343:481–492

    Article  CAS  Google Scholar 

  • Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D, Ceppi M, Bocchini V, Tichelli A, Socie G (2007) Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT late effects working party study. J Clin Oncol 25:2449–2454

    Article  PubMed  Google Scholar 

  • Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boice JD (1997) Solid cancers after bone marrow transplantation. N Eng J Med 336:897–904

    Article  CAS  Google Scholar 

  • Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94:2208–2216

    PubMed  CAS  Google Scholar 

  • Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van’t Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population- based evaluation over 25 years. J Clin Oncol 20:3484–3494

    Article  PubMed  Google Scholar 

  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS (1999) Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 17:3128–3135

    PubMed  CAS  Google Scholar 

  • Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers MED, Tichelli A, Sanders JE, Deeg HJ, Socie G (2008) Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 111:939–944

    Article  PubMed  CAS  Google Scholar 

  • Gilliland DG, Gribben JG (2002) Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 8:9–16

    Article  PubMed  CAS  Google Scholar 

  • Gulley ML, Tang W (2010) Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 23:350–366

    Article  PubMed  CAS  Google Scholar 

  • Hake CR, Graubert TA, Fenske TS (2007) Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 29:59–70

    Article  Google Scholar 

  • Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002–4008

    Article  PubMed  CAS  Google Scholar 

  • Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B (2006) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604–3610

    Article  PubMed  Google Scholar 

  • Kollmannsberger D, Hartmann JT, Kanz L, Bokemeyer C (1999) Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83:860–863

    Article  PubMed  CAS  Google Scholar 

  • Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992–5001

    Article  PubMed  CAS  Google Scholar 

  • Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24:1119–1126

    Article  PubMed  Google Scholar 

  • Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, Lee CH, Emanuel DJ (1998) Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91:3654–3661

    PubMed  CAS  Google Scholar 

  • Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A (2012) Recommended screening and preventative practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47:337–341

    Article  PubMed  CAS  Google Scholar 

  • Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabisi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O’Reilly RJ (1994) Infusions of donor leukocytes to treat Epstein-Barr virus- associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Eng J Med 330:1185–1191

    Article  CAS  Google Scholar 

  • Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2009) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273–3279

    Google Scholar 

  • Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175–1183

    Article  PubMed  CAS  Google Scholar 

  • Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E, Gural A, Shafran-Tikva S, Ben-Neriah S, Ben-Yehuda D (2005) Therapy related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 19:1919–1928

    Article  PubMed  CAS  Google Scholar 

  • Swerdlow SH, Webber SA, Chadburn A, Ferry J (2008) Post transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL (eds) Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 342–349

    Google Scholar 

  • Trappe R, Reiss H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dorken B, Oertel S (2007) Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 83:912–918

    Article  PubMed  CAS  Google Scholar 

  • van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loop AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Lowenberg B, Verdonck LF, Cornelissen JJ (2001) Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT. Blood 98:972–978

    Article  PubMed  Google Scholar 

  • van Esser JW, Niesters HG, van der Holt HB, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Lowenberg B, Cornelissen JJ (2002) Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364–4369

    Article  PubMed  Google Scholar 

  • Waterman J, Rybicki L, Bolwell B, Copelan E, Pohlman B, Sweetenham J, Dean R, Sobecks R, Andresen S, Kalaycio M (2012) Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 47:488–493

    Article  PubMed  CAS  Google Scholar 

  • Wiseman DH (2011) Donor cell leukemia: a review. Biol Blood Marrow Transplant 17:771–789

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Oncology and Transplantation, Department of Medicine, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN, 55455, USA

    Bryan Trottier & Linda J. Burns

Authors
  1. Bryan Trottier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda J. Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda J. Burns .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, Kean university, Room 213, Library Building, Union, New Jersey, USA

    M.A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Trottier, B., Burns, L.J. (2014). Autologous and Allogeneic Hematopoieitic Cell Transplantation: Risk of Second Malignancies. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 11. Stem Cells and Cancer Stem Cells, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7329-5_19

Download citation

Publish with us

Policies and ethics

Search

Navigation